Abstracts

1213 – Oral Fluid Concentrations of Tenofovir and Emtricitabine for Antiretroviral Adherence Monitoring

Background Adherence monitoring using drug concentrations for oral Pre-exposure Prophylaxis (PrEP) can identify people who need additional adherence support interventions or a transition to long-acting injectable regimens. Oral fluids are widely accepted as a convenient and confidential specimen type for HIV self-testing. This study evaluated the feasibility of detecting emtricitabine (FTC) and tenofovir (TFV) in…

1225 – Self-Reported Frequent vs Infrequent HIV Risk and Actual Diagnoses in MSM: Implications for PrEP

Background In Thailand, pre-exposure prophylaxis (PrEP) is primarily offered as a daily regimen and focuses on men who have sex with men (MSM) who report frequently engaging in condomless sex. However, MSM reporting less frequent HIV risk exposure may also benefit from PrEP. This retrospective study investigates HIV incidence based on self-reported risk frequency. Methods…

1193 – Use of DNA Profiling to Resolve Discrepant HIV Tests in the Setting of Injectable Cabotegravir PrEP

Background In clinical trials, discordant test results can complicate participant management and study endpoint determination. HIV diagnosis can be challenging when long-acting cabotegravir (CAB-LA) is used for HIV pre-exposure prophylaxis (PrEP) since HIV antigen, antibody, and RNA levels are often low. HIV assays can also revert from reactive/positive to non-reactive/negative in this setting. We evaluated…

1202 – Evaluating Pharmacy-Based PrEP Delivery for Sex Workers in Zimbabwe: Pilot Quasi-Experimental Study

Background Sex workers (SW) experience high HIV incidence, yet the potential benefit of daily oral pre-exposure prophylaxis (PrEP) is limited by poor continuation. Enabling pharmacy-based PrEP collection has potential to improve continuation among SW allowing anonymity, convenient location, long operating hours and shorter waiting times. We piloted pharmacy-based PrEP prescription refills to improve continuation; the…

1076 – Low Rates of HIV Pre-Exposure Prophylaxis Prescriptions Among US Youth in a Claims Database

Background Adolescents and young adults (AYA) ages 13-24 in the U.S. have disproportionately high rates of new HIV infections but major underuse of HIV preexposure prophylaxis (PrEP). We measured PrEP prescriptions among commercially-insured AYA in the US at increased risk for HIV during January 2018 to June 2023 and identified demographic, clinical, and geographic factors associated…

1235 – Cost-Effectiveness of Community Pharmacy-Based HIV PrEP for Men Who Have Sex With Men in Atlanta

Background The ongoing US HIV epidemic highlights the need for innovative strategies to promote pre-exposure prophylaxis (PrEP) uptake and reduce HIV incidence. Community pharmacy-based PrEP provides opportunity to expand access to this highly effective preventative therapy. Our study evaluated the potential health impacts, economic costs, and cost-effectiveness of community pharmacy-based PrEP for men who have…

1229 – The Cost-Effectiveness and Optimal Price Level of Injectable PrEP With Lenacapavir in South Africa

Background Injectable lenacapavir (LEN) has been shown to be 100% effective in protecting African women from HIV infection, but its acceptable price and cost-effectiveness is unknown. We estimated the impact of LEN compared to daily oral tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) and injectable cabotegravir (CAB) for HIV prevention in South Africa, and the threshold…